NCI Awards $2.3M Grant to Advance Possible Therapy for Triple-negative Breast Cancer

NCI Awards $2.3M Grant to Advance Possible Therapy for Triple-negative Breast Cancer
The National Cancer Institute has awarded a Fast Track Small Business Innovation Research grant to Agilvax to support development of the company’s lead immunotherapy candidate, AX09, for an aggressive and difficult-to-treat breast cancer. The grant, worth about $2.3 million, will go toward preclinical trials, a toxicology study, and the establishment of good manufacturing practices. Ultimately, it aims to enable the submission of AX09’s investigational new drug application (IND) to the U.S. Food and Drug Administration to begin clinical testing. The three most common types of receptors that fuel breast cancer growth are the estrogen, progesterone, and HER2. In some 20 percent of breast cancer patients, whose cancer is called triple-negative, these receptors are not present in the tumor. In these patients, treatments like hormone therapy or those that target estrogen, progesterone, and HER-2 are ineffective. Triple-negative breast cancer (TNBC) also tends to be more aggressive. AX09 is a virus-like-particle immunotherapy aiming to treat TNBC. It targets the stem cell protein xCT, found in a high percentage of breast cancers including TNBC. “We are delighted to receive this grant award from the National Cancer Institute (NCI) to advance the development of AX09 in TNBC, which is one of the lead indications for this product,” Federica Pericle, PhD, president and chief executive officer of Agilvax, said in a
Subscribe or to access all post and page content.